Inflammatory Bowel Disease - Non-biological treatment

Autores da FMUP

• Fernando José Magro Dias

  Autor

Participantes de fora da FMUP

• Cordeiro, G
• Dias, AM
• Estevinho, MM

Unidades de investigação

• Biomedicina

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Nowadays, non-biological treatments remain valuable approaches among the therapeutic armamentarium of inflammatory bowel disease (IBD). Mesalamine is the core treatment of mild-to-moderate ulcerative colitis (UC) and corticosteroids are crucial for the induction of remission of moderate-to-severe flares in both UC and Crohn's disease (CD). Even approaches as cyclosporine, tacrolimus, azathioprine, methotrexate, and surgery still have a nuclear position as strategies to induce and/or maintain remission in IBD. Due to their particularities and to the accumulated evidence, each of these strategies conquered peculiar roles in the overall IBD strategy, all of them contributing to better outcomes. This review emphasizes the particular roles that non-biological treatments gained over time: recent mesalamine formulations to increase adhesion rates, higher doses of 5-ASA for high-risk patients, MMX technology to improve drug release and attain higher bowel concentrations, cyclosporine as a bridge to vedolizumab, tacrolimus as a potential alternative to thiopurines or infliximab, azathioprine in combination therapy with infliximab and dubious in monotherapy, and surgery as a mean to a "better end".

Keywords

• Inflammatory Bowel Diseases; Crohn disease; Ulcerative colitis